Journal of Diabetes and Its Complications
Volume 21, Issue 3 , Pages 166-171 , May 2007

Peroxisome proliferator-activated receptor γ polymorphism Pro12Ala is associated with nephropathy in type 2 diabetes

  • Rebecca L. Pollex

      Affiliations

    • Robarts Research Institute, London, Ontario, Canada N6A 5K8
    • ,
  • Mary Mamakeesick

      Affiliations

    • Sandy Lake Health and Diabetes Project, Sandy Lake, Ontario, Canada
    • ,
  • Bernard Zinman

      Affiliations

    • Department of Medicine, University of Toronto and Leadership Sinai Centre for Diabetes, Mount Sinai Hospital, Toronto, Ontario, Canada M5G 1X5
    • ,
  • Stewart B. Harris

      Affiliations

    • Thames Valley Family Practice Research Unit, University of Western Ontario, London, Ontario, Canada
    • ,
  • Robert A. Hegele

      Affiliations

    • Robarts Research Institute, London, Ontario, Canada N6A 5K8
    • Corresponding Author InformationCorresponding authors. Robert A. Hegele is to be contacted at Blackburn Cardiovascular Genetics Laboratory, Robarts Research Institute, 100 Perth Drive, Room 406, London, Ontario, Canada N6A 5K8. Tel.: +1 519 663 3461; fax: +1 519 663 3037. Anthony J.G. Hanley, Leadership Sinai Centre for Diabetes, Lebovic Building, Room 5-210, Mount Sinai Hospital, 600 University Ave, Toronto, Ontario, Canada M5G 1X5. Tel.: +1 416 586 8441; fax: +1 416 586 8404.
    • ,
  • Anthony J.G. Hanley

      Affiliations

    • Department of Medicine, University of Toronto and Leadership Sinai Centre for Diabetes, Mount Sinai Hospital, Toronto, Ontario, Canada M5G 1X5
    • Corresponding Author InformationCorresponding authors. Robert A. Hegele is to be contacted at Blackburn Cardiovascular Genetics Laboratory, Robarts Research Institute, 100 Perth Drive, Room 406, London, Ontario, Canada N6A 5K8. Tel.: +1 519 663 3461; fax: +1 519 663 3037. Anthony J.G. Hanley, Leadership Sinai Centre for Diabetes, Lebovic Building, Room 5-210, Mount Sinai Hospital, 600 University Ave, Toronto, Ontario, Canada M5G 1X5. Tel.: +1 416 586 8441; fax: +1 416 586 8404.

Received 15 November 2005 ,Revised 14 February 2006 ,Accepted 28 February 2006.

References 

  1. Al-Shali KZ, House AA, Hanley AJ, Khan HM, Harris SB, Zinman B, et al. Genetic variation in PPARG encoding peroxisome proliferator-activated receptor gamma associated with carotid atherosclerosis. Stroke. 2004;35:2036–2040
  2. Altshuler D, Hirschhorn JN, Klannemark M, Lindgren CM, Vohl MC, Nemesh J, et al. The common PPARgamma Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes. Nature Genetics. 2000;26:76–80
  3. Argmann CA, Cock TA, Auwerx J. Peroxisome proliferator-activated receptor gamma: The more the merrier?. European Journal of Clinical Investigation. 2005;35:82–92(discussion, 80)
  4. Caramori ML, Canani LH, Costa LA, Gross JL. The human peroxisome proliferator-activated receptor gamma2 (PPARgamma2) Pro12Ala polymorphism is associated with decreased risk of diabetic nephropathy in patients with type 2 diabetes. Diabetes. 2003;52:3010–3013
  5. Deeb SS, Fajas L, Nemoto M, Pihlajamaki J, Mykkanen L, Kuusisto J, et al. A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nature Genetics. 1998;20:284–287
  6. Desvergne B, Michalik L, Wahli W. Be fit or be sick: Peroxisome proliferator-activated receptors are down the road. Molecular Endocrinology. 2004;18:1321–1332
  7. Fajas L, Auboeuf D, Raspe E, Schoonjans K, Lefebvre AM, Saladin R, et al. The organization, promoter analysis, and expression of the human PPARgamma gene. Journal of Biological Chemistry. 1997;272:18779–18789
  8. Hanley AJ, Harris SB, Mamakeesick M, Goodwin K, Fiddler E, Hegele RA, et al. Complications of type 2 diabetes among aboriginal Canadians: Prevalence and associated risk factors. Diabetes Care. 2005;28:2054–2057
  9. Hanley AJG, Harris SB, Barnie A, Gittelsohn J, Wolever TMS, Logan A, et al. The Sandy Lake Health and Diabetes Project: Design, methods and lessons learned. Chronic Diseases in Canada. 1995;16:149–156
  10. Hanley AJG, Harris SB, Mamakeesick M, Goodwin K, Fiddler E, Hegele RA, et al. Complications of type 2 diabetes among Native Canadians: Increasing our understanding of prevalence and risk factors. Canadian Journal of Diabetes. 2003;27:455–463
  11. Harris SB, Gittelsohn J, Hanley A, Barnie A, Wolever TM, Gao J, et al. The prevalence of NIDDM and associated risk factors in native Canadians. Diabetes Care. 1997;20:185–187
  12. Hegele RA, Cao H, Harris SB, Zinman B, Hanley AJ, Anderson CM. Peroxisome proliferator-activated receptor-gamma2 P12A and type 2 diabetes in Canadian Oji–Cree. Journal of Clinical Endocrinology and Metabolism. 2000;85:2014–2019
  13. Herrmann SM, Ringel J, Wang JG, Staessen JA, Brand E. Peroxisome proliferator-activated receptor-gamma2 polymorphism Pro12Ala is associated with nephropathy in type 2 diabetes: The Berlin Diabetes Mellitus (BeDiaM) Study. Diabetes. 2002;51:2653–2657
  14. Masugi J, Tamori Y, Mori H, Koike T, Kasuga M. Inhibitory effect of a proline-to-alanine substitution at codon 12 of peroxisome proliferator-activated receptor-gamma 2 on thiazolidinedione-induced adipogenesis. Biochemical and Biophysical Research Communications. 2000;268:178–182
  15. Meltzer S, Leiter L, Daneman D, Gerstein HC, Lau D, Ludwig S, et al. 1998 Clinical practice guidelines for the management of diabetes in Canada. Canadian Diabetes Association. Canadian Medical Association Journal. 1998;159(Suppl 8):S1–S29
  16. Parsons MP, Newman DJ, Newall RG, Price CP. Validation of a point-of-care assay for the urinary albumin:creatinine ratio. Clinical Chemistry. 1999;45:414–417
  17. Poulsen P, Andersen G, Fenger M, Hansen T, Echwald SM, Volund A, et al. Impact of two common polymorphisms in the PPARgamma gene on glucose tolerance and plasma insulin profiles in monozygotic and dizygotic twins: Thrifty genotype, thrifty phenotype or both?. Diabetes. 2003;52:194–198
  18. Ridker PM, Cook NR, Cheng S, Erlich HA, Lindpaintner K, Plutzky J, et al. Alanine for proline substitution in the peroxisome proliferator-activated receptor gamma-2 (PPARG2) gene and the risk of incident myocardial infarction. Arteriosclerosis, Thrombosis, and Vascular Biology. 2003;23:859–863
  19. Stumvoll M, Haring H. The peroxisome proliferator-activated receptor-gamma2 Pro12Ala polymorphism. Diabetes. 2002;51:2341–2347
  20. USRDS . U.S. Renal Data System 2004 annual data report: Atlas of end-stage renal disease in the United States. Bethesda, MD: National Institutes of Health; 2004;
  21. Wilson R, Krefting LH, Sutcliffe P, VanBussel L. Incidence and prevalence of end-stage renal disease among Ontario's James Bay Cree. Canadian Journal of Public Health. 1992;83:143–146
  22. Young TK, Kaufert JM, McKenzie JK, Hawkins A, O'Neil J. Excessive burden of end-state renal disease among Canadian Indians: A national survey. American Journal of Public Health. 1989;79:756–758
  23. Young TK, Reading J, Elias B, O'Neil JD. Type 2 diabetes mellitus in Canada's first nations: Status of an epidemic in progress. Canadian Medical Association Journal. 2000;163:561–566

PII: S1056-8727(06)00028-6

doi: 10.1016/j.jdiacomp.2006.02.006

Journal of Diabetes and Its Complications
Volume 21, Issue 3 , Pages 166-171 , May 2007

Article Tools